Stockreport

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

VYNE Therapeutics Inc.  (VYNE) 
PDF Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025VYN202 Phase 1b psoriasis trial initiated with results anticipated by year-end 2025Expecte [Read more]